Effects of CB2 Receptor Agonist JWH133 on Aβ42-Induced Hippocampal Neurons

Effects of CB2 Receptor Agonist JWH133 on Aβ42-Induced Hippocampal Neurons

Loading document ...
Loading page ...


Author(s): Jingfu Zhao

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.2353 15 47 1-4 Volume 9 - Jun 2020


Objective To observe the effects of Cannabinoid type 2 receptor (CB2R) on Aβ-induced hippocampal neuron. Methods Hippocampal neurons were pre-treated with 10 μM JWH133 and then treated 100 nM Aβ42 oligomer for 7 day, the mRNA of Bcl-2 and Bax was measured by qRT-PCR, and the mitochondrial membrane potential and the production of ROS were measured by Flow Cytometry. Result Aβ42 oligomer significantly decreased the ratio of Bcl-2/Bax, and mitochondrial membrane potential, and increased the production of ROS. However, the pre-treatment JWH133 inhibited Aβ42-induced the ratio of Bcl-2/Bax decrease, and increased the mitochondrial membrane potential, decreased the production of ROS. Conclusion Activation of CB2R could inhibit the effects of Aβ42 on hippocampal neurons.


Primary Hippocampal Neuron, Amyloid Β-Protein, Cannabinoid Type 2 Receptor, JWH133


  1. Lane, C.A., J. Hardy, and J.M. Schott, Alzheimer's disease. Eur J Neurol, 2018. 25(1): p. 59-70.
  2. Bondi, M.W., E.C. Edmonds, and D.P. Salmon, Alzheimer's Disease: Past, Present, and Future. J Int Neuropsychol Soc, 2017. 23(9-10): p. 818-831.
  3. Mantzavinos, V. and A. Alexiou, Biomarkers for Alzheimer's Disease Diagnosis. Curr Alzheimer Res, 2017. 14(11): p. 1149-1154.
  4. Galla, L., et al., Intracellular Calcium Dysregulation by the Alzheimer's Disease-Linked Protein Presenilin 2. Int J Mol Sci, 2020. 21(3).
  5. Cheignon, C., et al., Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol, 2018. 14: p. 450-464.
  6. Bloom, G.S., Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol, 2014. 71(4): p. 505-8.
  7. Kowalski, K. and A. Mulak, Brain-Gut-Microbiota Axis in Alzheimer's Disease. J Neurogastroenterol Motil, 2019. 25(1): p. 48-60.
  8. Gosztyla, M.L., H.M. Brothers, and S.R. Robinson, Alzheimer's Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence. J Alzheimers Dis, 2018. 62(4): p. 1495-1506.
  9. Nazem, A., et al., Rodent models of neuroinflammation for Alzheimer's disease. J Neuroinflammation, 2015. 12: p. 74.
  10. Zhang, P., et al., Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model. Nat Neurosci, 2019. 22(5): p. 719-728.
  11. Stempel, A.V., et al., Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus. Neuron, 2016. 90(4): p. 795-809.
  12. Wu, Q. and H. Wang, The spatiotemporal expression changes of CB2R in the hippocampus of rats following pilocarpine-induced status epilepticus. Epilepsy Res, 2018. 148: p. 8-16.
  13. Wu, J., Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow. Acta Pharmacol Sin, 2019. 40(3): p. 297-299.
  14. Ward, S.J., et al., Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci, 2018. 195: p. 1-5.
  15. Wang, L., et al., Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway. Mol Neurobiol, 2018. 55(6): p. 4731-4744.
  16. Li, C., et al., CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP/PS1 mice. Neurosci Lett, 2019. 707: p. 134286.
  17. Siddiqui, W.A., A. Ahad, and H. Ahsan, The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol, 2015. 89(3): p. 289-317.
  18. Kontos, C.K., M.I. Christodoulou, and A. Scorilas, Apoptosis-related BCL2-family members: Key players in chemotherapy. Anticancer Agents Med Chem, 2014. 14(3): p. 353-74.
  19. Reyna, D.E., et al., Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell, 2017. 32(4): p. 490-505.e10.
  20. Blennow, K. and H. Zetterberg, Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med, 2018. 284(6): p. 643-663.
  21. Rosenberg, R.N., et al., Genomics of Alzheimer Disease: A Review. JAMA Neurol, 2016. 73(7): p. 867-74.
  22. Zhou, H., et al., Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. Acs Chemical Neuroscience, 2017: p. acschemneuro.7b00003.
  23. Leinwand, K.L., et al., Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease. Journal of Crohns & Colitis, 2017. 11(11): p. 1369.
  24. Solas, M., et al., CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging, 2013. 34(3): p. 805-8.
  25. Ly, J.D., D.R. Grubb, and A. Lawen, The mitochondrial membrane potential (Δψm) in apoptosis; An update. Apoptosis An International Journal on Programmed Cell Death, 2003. 8(2): p. 115-128.
  26. Jurgensmeier, et al., Bax directly induces release of cytochrome c from isolated mitochondria. Proceedings of the National Academy of Sciences of the United States of America, 1998.
  27. Bedard, et al., The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology. Physiological Reviews, 2007.

Cite this Article:

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue April 2021

Volume 10, April 2021

Table of Contents

World-wide Delivery is FREE

Share this Issue with Friends:

Submit your Paper